Silo Pharma, Inc. (SILO) Latest Company News

Oct 16, 2026, 13:03 UTC
Change Agents Corporation appointed Eric Weisblum as an independent director, effective October 12, 2026.
Oct 14, 2026, 20:34 UTC
Silo Pharma acquired certain software and related intellectual property from Larry King in exchange for 150,000 shares of common stock, subject to a 12-month lock-up.
Oct 2, 2026, 20:50 UTC
Silo Pharma, Inc. issued a warrant to Norsight Consulting Inc. to purchase up to 300,000 shares of common stock at an exercise price of $1.51 per share in a private placement.
Aug 19, 2026, 00:00 UTC
Silo Pharma, Inc. issued 165,000 shares of common stock to Parkview Consulting LLC in a private placement exempt under Section 4(a)(2) of the Securities Act of 1933, with a 12-month lock-up period, as disclosed in an 8-K filed on August 18, 2026.
Jul 14, 2026, 12:55 UTC
Silo Pharma's subsidiary QwikAgents was accepted into Advanced Micro Devices' AMD AI Developer Program.
Source:
- globenewswire.com
Jul 13, 2026, 00:00 UTC
Silo Pharma, Inc. entered into securities purchase agreements and completed a private placement, selling common shares, pre-funded warrants, and Series A-3/Series A-4 warrants to institutional investors for aggregate gross proceeds of approximately $4,000,015.
Jul 7, 2026, 18:18 UTC
NVIDIA Corp. expanded its presence in life sciences AI through separate initiatives with Certara Inc. and Silo Pharma Inc.
Source:
- benzinga.com
Jun 18, 2026, 12:12 UTC
Silo Pharma regained compliance with Nasdaq's minimum bid price requirement as of June 17, 2026.

SILO

Change Agents Corporation appointed Eric Weisblum as an independent director, effective October 12, 2026.

Silo Pharma acquired certain software and related intellectual property from Larry King in exchange for 150,000 shares of common stock, subject to a 12-month lock-up.

Silo Pharma, Inc. issued a warrant to Norsight Consulting Inc. to purchase up to 300,000 shares of common stock at an exercise price of $1.51 per share in a private placement.

Silo Pharma, Inc. issued 165,000 shares of common stock to Parkview Consulting LLC in a private placement exempt under Section 4(a)(2) of the Securities Act of 1933, with a 12-month lock-up period, as disclosed in an 8-K filed on August 18, 2026.

Silo Pharma's subsidiary QwikAgents was accepted into Advanced Micro Devices' AMD AI Developer Program.

Silo Pharma, Inc. entered into securities purchase agreements and completed a private placement, selling common shares, pre-funded warrants, and Series A-3/Series A-4 warrants to institutional investors for aggregate gross proceeds of approximately $4,000,015.

NVIDIA Corp. expanded its presence in life sciences AI through separate initiatives with Certara Inc. and Silo Pharma Inc.

Silo Pharma regained compliance with Nasdaq's minimum bid price requirement as of June 17, 2026.